MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Country |
 USA |
IPO year |
1992 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
1.24 B |
Market Cap[1] |
$ 171 B |
EBITDA (LTM) |
$ 9.3 B |
P/E (LTM) |
23.17 |
P/S (LTM) |
6.04 |
EPS (LTM) |
6.09 |
Gilead Sciences is an American biopharmaceutical company that specializes in the development and production of innovative drugs for the treatment of various diseases.
The company was founded in 1987 and is currently one of the leaders in the field of biotechnology. It conducts research and development in areas such as infectious diseases, oncology, hepatitis, HIV infection, and other areas of medicine.
The company's most well-known and successful product is Sovaldi, which is the first drug to effectively treat chronic hepatitis C. The company also produces drugs for the treatment of blood cancer and HIV infection.
Gilead Sciences actively collaborates with scientific and medical institutions around the world and invests in the development of new methods for treating diseases. The company also provides training programs for medical professionals and patients.
Gilead Sciences continues to grow and expand its activities to help people around the world fight various diseases.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
$ 28.46 | 3.45 % | $ 319 M | Nasdaq Global Select Market,SPB | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 221.88 | -0.87 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Axsome Therapeutics
AXSM
|
$ 156.92 | -1.23 % | $ 7.81 B | Nasdaq Global Market,SPB | USA |
 |
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | USA |
 |
Pharming Group N.V.
PHAR
|
$ 15.36 | -0.71 % | $ 7.59 B | Nasdaq Global Select Market |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.37 | -4.2 % | $ 350 M | Nasdaq Global Select Market |  Britain |
 |
Kamada Ltd.
KMDA
|
$ 8.5 | -1.39 % | $ 260 M | Nasdaq Global Select Market |  Israel |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Benitec Biopharma
BNTC
|
$ 10.98 | -4.52 % | $ 452 M | Nasdaq Capital Market | USA |
 |
Inventiva S.A.
IVA
|
$ 5.78 | -4.3 % | $ 138 M | Nasdaq Global Market | France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Compugen Ltd.
CGEN
|
$ 2.09 | -0.95 % | $ 195 M | Nasdaq Global Market,SPB | Israel |
 |
Tiziana Life Sciences PLC
TLSA
|
$ 1.21 | -3.97 % | $ 71.5 M | Nasdaq Global Market | Britain |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
PainReform Ltd.
PRFX
|
$ 2.28 | -0.44 % | $ 1.03 M | Nasdaq Capital Market | Israel |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
|
Foghorn Therapeutics
FHTX
|
$ 5.0 | 2.25 % | $ 315 M | Nasdaq Global Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 3.4 | -3.68 % | $ 1.02 B | Nasdaq Global Select Market | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
$ 54.13 | -1.64 % | $ 10.4 B | Nasdaq Global Select Market,SPB | USA |
 |
Curis
CRIS
|
$ 0.77 | 1.89 % | $ 4.86 M | Nasdaq Global Market | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.52 | -5.59 % | $ 178 M | Nasdaq Global Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Burford Capital Limited
BUR
|
$ 7.7 | -5.87 % | $ 1.29 B | NYSE | Britain |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectis S.A.
CLLS
|
$ 3.34 | -4.02 % | $ 116 M | Nasdaq Global Market | France |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.24 | -2.97 % | $ 704 M | Nasdaq Global Select Market | Canada |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.8 | -1.1 % | $ 120 M | Nasdaq Capital Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Cabaletta Bio
CABA
|
$ 2.94 | -3.29 % | $ 3.43 M | Nasdaq Global Select Market | USA |
 |
Iterum Therapeutics
ITRM
|
$ 0.16 | -5.45 % | $ 3.15 M | Nasdaq Global Select Market |  Irlanda |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.